The only targeted therapy approved in R/M HNSCC is the antibody against EGFR, cetuximab (Licitra et al., 2011, 2013), pembrolizumab (Seiwert et al., 2016), and nivolumab (Ferris et al., 2016) targeting PD-1 examples for immune-CPI. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.